Completed PHASE2 INTERVENTIONAL 1-arm NCT01538641

Phase II Evaluation of Gemcitabine- Rituximab-Oxaliplatin Combination (GROC) in Relapsed Aggressive Lymphomas

Phase II Evaluation Of GROC (Gemcitabine- Rituximab-Oxaliplatin Combination) Given Every 14 Days For The Treatment Of Patients With Relapsed Or Refractory Aggressive Non-Hodgkin's Lymphoma

Sponsor: Auxilio Mutuo Cancer Center

Conditions Refractory Aggressive Non-Hodgkin's Lymphoma Relapsing Aggressive Non-Hodgkin's Lymphoma

Interventions Rituximab, Gemcitabine, Oxaliplatin

Updated 6 times since 2017 Last updated: Jul 11, 2012 Started: Oct 31, 2003 Primary completion: Aug 31, 2007 Completion: Dec 31, 2008

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2 clinical study on Refractory Aggressive Non-Hodgkin's Lymphoma and Relapsing Aggressive Non-Hodgkin's Lymphoma, this trial is completed. The trial is conducted by Auxilio Mutuo Cancer Center and has accumulated 6 data snapshots since 2003. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2
Feb 2017 — Jun 2018 [monthly]

Completed PHASE2

▶ Show 1 earlier version

Jan 2017 — Feb 2017 [monthly]

Completed PHASE2

First recorded

Oct 2003

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Auxilio Mutuo Cancer Center

Data source: Auxilio Mutuo Cancer Center

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

No location information available.